EPCORE™ DLBCL-4

M22-128

Don't face the journey with lymphoma *alone.*

The journey with diffuse large b-cell lymphoma shouldn't be a lonely one—join a growing community of people seeking answers through clinical research. Consider participating in the EPCORE DLBCL-4 clinical research study.

The EPCORE DLBCL-4 Clinical Research Study

The EPCORE DLBCL-4 Study is evaluating the safety and effectiveness of a study drug in combination with an approved anti-lymphoma drug compared to standard-of-care treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Although the study drug is approved for treating certain patients with DLBCL, its use in this study is considered investigational since its safety and effectiveness for the intended investigational purpose have not yet been established.

You may be able to take part in the EPCORE DLBCL-4 Study if you:

- Are at least 18 years old
- Have been diagnosed with relapsed or refractory DLBCL
  - Relapsed: Your lymphoma previously responded to therapy but progressed 6 months or later after completing therapy
  - Refractory: Your lymphoma either progressed during therapy, did not respond to prior therapy, or progressed within 6 months after completing therapy (including maintenance therapy)
- Have received at least 1 prior systemic anti-lymphoma therapy and progressed after, or are ineligible for or unable to receive, CAR-T therapy or autologous stem cell transplant
  - Systemic therapy: Treatment that travels through your bloodstream

If you are interested in participating, the study doctor and staff will review additional eligibility criteria with you.

FAQs

What's involved with participation in the EPCORE DLBCL-4 Study?

- Participants will be assigned to receive either the study drug in combination with an approved anti-lymphoma drug or standard-of-care treatment alone while completing various study tests and procedures.
- All participants will receive study treatment. There is no placebo in this study.
- The study drug will be given as a subcutaneous injection (under the skin) in combination with an approved anti-lymphoma drug that will be administered as an oral capsule. The standard-of-care treatment is a combination of 3 drugs that will be given through an intravenous injection (delivered through a tiny tube into the vein).
- Participants may leave the study at any point in time.

Does participating in this study cost anything?

If you qualify for and agree to participate in the study, you will not have to pay for the study drugs. In addition, reimbursement for study-related travel expenses may be available.

If prequalified, what can I expect on my first visit to the study clinic?

This initial appointment is an opportunity for you to:

- **Ask any important questions you may have.** These can be any questions you may have about this study or clinical research in general.
- **Determine if the EPCORE DLBCL-4 Study may be right for you.** You will speak with a member of the site staff and learn more about the study. You will be asked about your health history to determine if you are eligible for the study. If you are eligible, you will be given the opportunity to decide if participation is right for you. If you agree to take part, you will be asked to review and sign a consent form for study participation. You can also leave the study at any time. Once you have signed the study consent form, the research staff will perform a series of tests to determine if you are right for the study, and if the study is right for you.

What if my condition worsens or I have side effects?

You should make sure to inform your doctor of any new symptoms you experience while participating in the study. If you experience worsening or improvement of your disease or side effects at any time during the study, please let the study doctor and staff know.

Where are the study clinics located?

There are study clinics located throughout the world. Find a location near you: **EPCORE-trials.com/locations**.

EPCORE™ DLBCL-4

M22-128

This research study is evaluating the safety and effectiveness of an approved drug for a specific investigational use that is currently not approved by regulatory health authorities.